Bicara Therapeutics (BCAX) Depreciation & Amortization (CF) (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Depreciation & Amortization (CF) of $44000.0 for Q1 2026, up 131.58% year-over-year from $19000.0 in Q1 2025, and up 2.33% quarter-over-quarter from $43000.0 in Q4 2025.
Bicara Therapeutics (BCAX) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at $44000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 131.58% year-over-year to $44000.0; the TTM figure through Mar 2026 stood at $130000.0 (up 109.68% YoY), while the FY2025 annual figure was $105000.0, up 87.5% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $44000.0, up from $43000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $44000.0 in Q1 2026, with the low at $13000.0 in Q1 2024.
- The 4-year median for Depreciation & Amortization (CF) is $17000.0 (2024), against an average of $21900.0.
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) grew 7.14% in 2024, then jumped 186.67% in 2025.
- Bicara Therapeutics' Depreciation & Amortization (CF) stood at $14000.0 in 2023, then increased by 7.14% to $15000.0 in 2024, then surged by 186.67% to $43000.0 in 2025, then grew by 2.33% to $44000.0 in 2026.
- Business Quant data shows BCAX's Depreciation & Amortization (CF) at $44000.0 in Q1 2026, $43000.0 in Q4 2025, and $24000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44,000.00 |
| Jun 30, 2026 | 44,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Mar 31, 2024 | 13,000.00 |